In an interview with Pharmacy Times, Ming-Hei Tai, PharmD, BCOP, discusses emerging bladder-preserving therapies for NMIBC, the limitations of single-arm trial data, the continued role of BCG, and the clinical and operational factors that should guide treatment selection.

Morning appointments don't appear to offer any immunologic edge over afternoon ones, new data from more than 15 million patients suggest.

A 19-protein plasma panel predicted whether and when presymptomatic carriers of ALS-associated pathogenic variants would develop clinically manifest disease more accurately than neurofilament light chain alone.

Advance verification, multidisciplinary coordination, and AI-enabled forecasting can help infusion centers adjust schedules and treatment plans during chemotherapy shortages.

Zepcan walks through what a complete pharmacist-to-pharmacist handoff should include when a patient with AML on a menin inhibitor moves from an academic center to community care, covering dosing history, QTc and laboratory test baselines, and documented counseling.

Zahra Mahmoudjafari noted that while patients with high disease burden, a history of severe cytokine release syndrome (CRS) or neurotoxicity, poor performance status, or limited caregiver support were historically considered less suitable for community-based administration, significant progress has been made as community centers develop strong patient selection criteria, outpatient roadmaps, and escalation strategies, often in partnership with academic centers for initial step-up dosing.